Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Not yet recruiting · NCT04622566 · Registry updated 2020-11-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | mucosal melanoma | Not yet recruiting | Phase 2 | 2020-11-13 | NCT04622566 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University Cancer Hospital & Institute | 189 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | 208 |